Adaptimmune Therapeutics Plc Stock Market Value
| ADAP Stock | USD 0.66 0.02 3.13% |
| Symbol | Adaptimmune |
Adaptimmune Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptimmune Therapeutics. If investors know Adaptimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptimmune Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.17) | Revenue Per Share 0.595 | Quarterly Revenue Growth 23.996 | Return On Assets (0.16) | Return On Equity (0.65) |
The market value of Adaptimmune Therapeutics is measured differently than its book value, which is the value of Adaptimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptimmune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Adaptimmune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptimmune Therapeutics' market value can be influenced by many factors that don't directly affect Adaptimmune Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptimmune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptimmune Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptimmune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Adaptimmune Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Adaptimmune Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Adaptimmune Therapeutics.
| 10/26/2024 |
| 11/25/2024 |
If you would invest 0.00 in Adaptimmune Therapeutics on October 26, 2024 and sell it all today you would earn a total of 0.00 from holding Adaptimmune Therapeutics Plc or generate 0.0% return on investment in Adaptimmune Therapeutics over 30 days. Adaptimmune Therapeutics is related to or competes with Stoke Therapeutics, Black Diamond, Mereo BioPharma, Pieris Pharmaceuticals, PDS Biotechnology, Leap Therapeutics, and Affimed NV. Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies prim... More
Adaptimmune Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Adaptimmune Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Adaptimmune Therapeutics Plc upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.19) | |||
| Maximum Drawdown | 33.29 | |||
| Value At Risk | (6.00) | |||
| Potential Upside | 5.56 |
Adaptimmune Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adaptimmune Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Adaptimmune Therapeutics' standard deviation. In reality, there are many statistical measures that can use Adaptimmune Therapeutics historical prices to predict the future Adaptimmune Therapeutics' volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (0.93) | |||
| Total Risk Alpha | (1.50) | |||
| Treynor Ratio | (0.52) |
Adaptimmune Therapeutics Backtested Returns
Adaptimmune Therapeutics secures Sharpe Ratio (or Efficiency) of -0.19, which signifies that the company had a -0.19% return per unit of standard deviation over the last 3 months. Adaptimmune Therapeutics Plc exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Adaptimmune Therapeutics' risk adjusted performance of (0.11), and Mean Deviation of 3.18 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.45, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Adaptimmune Therapeutics will likely underperform. At this point, Adaptimmune Therapeutics has a negative expected return of -0.87%. Please make sure to confirm Adaptimmune Therapeutics' standard deviation, kurtosis, period momentum indicator, as well as the relationship between the maximum drawdown and day median price , to decide if Adaptimmune Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.61 |
Very good reverse predictability
Adaptimmune Therapeutics Plc has very good reverse predictability. Overlapping area represents the amount of predictability between Adaptimmune Therapeutics time series from 26th of October 2024 to 10th of November 2024 and 10th of November 2024 to 25th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Adaptimmune Therapeutics price movement. The serial correlation of -0.61 indicates that roughly 61.0% of current Adaptimmune Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.61 | |
| Spearman Rank Test | 0.08 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Adaptimmune Therapeutics lagged returns against current returns
Autocorrelation, which is Adaptimmune Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Adaptimmune Therapeutics' stock expected returns. We can calculate the autocorrelation of Adaptimmune Therapeutics returns to help us make a trade decision. For example, suppose you find that Adaptimmune Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Adaptimmune Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Adaptimmune Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Adaptimmune Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Adaptimmune Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Adaptimmune Therapeutics Lagged Returns
When evaluating Adaptimmune Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Adaptimmune Therapeutics stock have on its future price. Adaptimmune Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Adaptimmune Therapeutics autocorrelation shows the relationship between Adaptimmune Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Adaptimmune Therapeutics Plc.
Regressed Prices |
| Timeline |
Pair Trading with Adaptimmune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptimmune Stock
| 0.75 | ME | 23Andme Holding | PairCorr |
| 0.91 | VALN | Valneva SE ADR | PairCorr |
| 0.71 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Adaptimmune Stock
| 0.63 | KZR | Kezar Life Sciences | PairCorr |
| 0.46 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.32 | MDGL | Madrigal Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.